The NCT04024761 trial is studying cytokine-induced memory-like natural killer (CIML-NK) cells plus IL-2 which leads to activation and expansion of the NK cells [14] in patients above 12 years with myeloid malignancies who relapsed or remain MRD positive after haploidentical HSCT. The gene discussed is IL2; the disease is myeloid neoplasm.